Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Kurose, Yuko ^a   Wada, Jun ^a   Kanzaki, Motoko ^a   Teshigawara, Sanae ^a   Nakatsuka, Atsuko ^a   Murakami, Kazutoshi ^a   Inoue, Kentaro ^a   Terami, Takahiro ^a   Katayama, Akihiro ^a   Watanabe, Mayu ^a   Higuchi, Chigusa ^a   Eguchi, Jun ^a   Miyatake, Nobuyuki ^b   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Glomerular filtration; Inflammation; Kidney disease; Nephropathy; Type 2 diabetes

Indexed keywords

CHOLESTEROL; CREATININE; ECALECTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALBUMINURIA; ARTICLE; CELL CYCLE REGULATION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE STATUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC PRESSURE; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

BIOLOGICAL MARKERS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GALECTINS; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84872475119     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-23     Document Type: Article

References (20)

1. Galectins: a family of animal beta-galactoside-binding lectins. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Cell 1994 76 4 597 598 10.1016/0092-8674(94) 90498-7 8124704 (Pubitemid 24070645)
2. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS, J Clin Invest 1997 99 10 2452 2461 10.1172/JCI119429 9153289 (Pubitemid 27227724)
3. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. Wada J, Kanwar YS, J Biol Chem 1997 272 9 6078 6086 10.1074/jbc.272.9.6078 9038233 (Pubitemid 27102450)
4. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. Tureci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U, J Biol Chem 1997 272 10 6416 6422 10.1074/jbc.272.10.6416 9045665 (Pubitemid 27118120)
5. Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats. Tsuchiyama Y, Wada J, Zhang H, Morita Y, Hiragushi K, Hida K, Shikata K, Yamamura M, Kanwar YS, Makino H, Kidney Int 2000 58 5 1941 1952 10.1111/j.1523-1755.2000.00366.x 11044214
6. The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Wang F, He W, Zhou H, Yuan J, Wu K, Xu L, Chen ZK, Cell Immunol 2007 250 1-2 68 74 18353298
7. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK, Nat Immunol 2005 6 12 1245 1252 10.1038/ni1271 16286920 (Pubitemid 43045636)
8. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms. Baba M, Wada J, Eguchi J, Hashimoto I, Okada T, Yasuhara A, Shikata K, Kanwar YS, Makino H, J Am Soc Nephrol 2005 16 11 3222 3234 10.1681/ASN.2004110915 16177004 (Pubitemid 46179328)
9. Revised equations for estimated GFR from serum creatinine in Japan. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Am J Kidney Dis 2009 53 6 982 992 10.1053/j.ajkd.2008.12. 034 19339088
10. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU, Kidney Int 2011 80 1 17 28 10.1038/ki.2010.483 21150873
11. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, Randall JA, McMahan R, Zimmerman MA, Rangachari M, Dobrinskikh E, Busson P, Polyak SJ, Hirashima M, Rosen HR, PLoS One 2010 5 3 9504 10.1371/journal.pone.0009504 20209097
12. Galectin-9 induced by dietary synbiotics is involved in suppression of allergic symptoms in mice and humans. de Kivit S, Saeland E, Kraneveld AD, van de Kant HJ, Schouten B, van Esch BC, Knol J, Sprikkelman AB, van der Aa LB, Knippels LM, Garssen J, van Kooyk Y, Willemsen LE, Allergy 2012 67 3 343 352 10.1111/j.1398-9995.2011.02771.x 22229637
13. Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. Imaizumi T, Kumagai M, Sasaki N, Kurotaki H, Mori F, Seki M, Nishi N, Fujimoto K, Tanji K, Shibata T, Tamo W, Matsumiya T, Yoshida H, Cui XF, Takanashi S, Hanada K, Okumura K, Yagihashi S, Wakabayashi K, Nakamura T, Hirashima M, Satoh K, J Leukoc Biol 2002 72 3 486 491 12223516
14. Regulatory mechanisms of galectin-9 and eotaxin-3 synthesis in epidermal keratinocytes: possible involvement of galectin-9 in dermal eosinophilia of Th1-polarized skin inflammation. Igawa K, Satoh T, Hirashima M, Yokozeki H, Allergy 2006 61 12 1385 1391 10.1111/j.1398-9995.2006.01130.x 17073866 (Pubitemid 44665300)
15. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Kanzaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, Inoue K, Terami T, Katayama A, Eguchi J, Akiba H, Yagita H, Makino H, Endocrinology 2012 153 2 612 620 10.1210/en.2011-1579 22186414
16. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F, Adhikary D, Mautner J, Busson P, Blood 2009 113 9 1957 1966 10.1182/blood-2008-02-142596 19005181
17. Protein release through nonlethal oncotic pores as an alternative nonclassical secretory pathway. Chirico WJ, BMC Cell Biol 2011 12 46 10.1186/1471-2121-12-46 22008609
18. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, Gutierrez-Ramos JC, Coyle AJ, Strom TB, Nat Immunol 2003 4 11 1093 1101 10.1038/ni987 14556005 (Pubitemid 37428037)
19. Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. Sehrawat S, Reddy PB, Rajasagi N, Suryawanshi A, Hirashima M, Rouse BT, PLoS Pathog 2010 6 5 1000882 10.1371/journal.ppat.1000882 20463811
20. Tim3 binding to galectin-9 stimulates antimicrobial immunity. Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, Kuchroo VK, Behar SM, J Exp Med 2010 207 11 2343 2354 10.1084/jem.20100687 20937702